Macquarie Group
IDXG

Macquarie Group’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Macquarie Group’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-740
Closed -$6K – 2263
2018
Q4 		$6K Buy
+740
New +$8.88K ﹤0.01% 2084

Other funds holding IDXG

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Macquarie Group's IDXG Position: Q1 2019 in Review

Macquarie Group sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2019, closing a stake of 740 shares — an estimated $6K sold.

Macquarie Group first reported a position in IDXG in Q4 2018 and held it in 1 quarter. The position peaked at $6K in Q4 2018. 20 funds tracked by Wall St. Rank hold IDXG as of Q1 2019.

  • Macquarie Group reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 740 Interpace Biosciences, Inc. Common Stock shares in Q1 2019, an estimated $6K.
  • Macquarie Group first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Macquarie Group's Interpace Biosciences, Inc. Common Stock position peaked at $6K in Q4 2018.
  • 20 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.